ADTX - Evofem Biosciences achieves 2023 prelim net product sales of $18.1M to $18.3M February, 01 2024 08:48 AM ADiTx Therapeutics Inc. 2024-02-01 08:48:44 ET More on Evofem Biosciences Aditxt to acquire women’s health company Evofem Biosciences Seeking Alpha’s Quant Rating on Evofem Biosciences Historical earnings data for Evofem Biosciences Financial information for Evofem Biosciences For further details see: Evofem Biosciences achieves 2023 prelim net product sales of $18.1M to $18.3M